Role of Mitochondrial Inheritance on Prostate Cancer Outcome in African-American Men

PRINCIPAL INVESTIGATOR: Martha Mims

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, TX 77030

REPORT DATE: October 2014

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**Report Date:** October 2014  
**Report Type:** Annual  
**Dates Covered:** 30 Sept 2013-29 Sept 2014  

**Title and Subtitle:** Role of Mitochondrial Inheritance on Prostate Cancer Outcome in African-American Men

**Authors:** Martha Mims  
E-Mail: mmims@bcm.edu

**Performing Organization:** Baylor College of Medicine  
Houston, Texas 77030-3498

**Sponsoring Agency:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**Abstract:** We are examining the hypothesis that mitochondrial inheritance plays a significant role in aggressiveness of prostate cancer in African Americans. In the first year of the project we identified 2,000 noncancerous tissues samples from African American men with prostate cancer and we have extracted DNA from ~1,500 of them to date. We have validated a robust new DNA sequencing technique developed by our collaborator using single amplicon long-range PCR that permits deep coverage (10,000-20,000X on average) of the mitochondrial genome. We have sequenced 652 samples fully thus far and FFPE samples are now in the pipeline. Mapping of DNA variants in our sequenced genomes to mitochondrial genes has begun and the initial data is presented here. After months of testing, we determined that the ethidium bromide methodology for generating prostate cancer cell line cybrids was not effective and we have instead decided to use the Rhodamine-6G procedure. Thus far PNT1A cybrid cell lines have been generated and we are actively characterizing these cells. PC3 cells have been more difficult, but we continue to work on this cell line.

**Subject Terms:** Mitochondrial DNA sequencing, Prostate cancer, Cybrid cells, African Americans.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4-15</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>15</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>15</td>
</tr>
<tr>
<td>Conclusion</td>
<td>15</td>
</tr>
<tr>
<td>References</td>
<td>16</td>
</tr>
<tr>
<td>Appendices</td>
<td>17-22</td>
</tr>
</tbody>
</table>
Introduction:
African American men are disproportionately affected by prostate cancer with increased lifetime risk, earlier onset of disease and more advanced stage at diagnosis than Caucasians. Prostate cancer is the leading cause of cancer death in African American men, with mortality more than double that observed in Caucasians. There are nearly 20 million African American men in the US, many of whom face significant risk of developing and dying from prostate cancer. Risk for and aggressiveness of prostate cancer in African American men is thought to originate in part from genetic susceptibility. Several nuclear genes and chromosomal regions have been linked to prostate cancer; however, many studies have not included African American men, and no study has linked genetic polymorphisms with clinical outcome. One factor which has not been carefully examined is mitochondrial inheritance which varies significantly between ethnic and racial groups and could explain large differences in disease characteristics. In the present study, we are examining the hypothesis that mitochondrial inheritance plays a significant role in aggressiveness of prostate cancer in African Americans. Further, we predict that adverse clinical outcomes will be reflected in dysregulation of cellular biochemical processes and in alterations in signaling pathways (Akt pathway, apoptosis). The ability to identify mitochondrial variants or haplogroups that contribute to aggressive disease will help to separate patients with indolent disease who can be spared unnecessary intervention from those who need more immediate and aggressive therapy. Identification of cellular pathways involved will help to target treatment strategies for those with cancers predicted to be more aggressive. In Aim 1 we will conduct a study of mitochondrial inheritance in 1,000 African American men with prostate cancer. We will sequence the mitochondrial genome of all 1,000 samples and determine whether particular mitochondrial variants, genes or haplogroups are associated with markers of aggressive disease (age at diagnosis, stage at diagnosis (including bone metastasis), Gleason score, PSA at diagnosis, PSA recurrence and death from disease). Findings will be replicated using an independent set of 1,000 patients from our own tissue resource with linked clinical data. Our strategy will be to sequence the mitochondrial DNA of all 1,000 patients in the discovery phase as well as in the replication group. We will control for population admixture using the Illumina African American Admixture Panel. Using cybrid technology, we will introduce our previously identified mt10398A variant and mitochondrial variants associated with highly aggressive and least aggressive disease identified in our genotyping study into prostate cell lines (derived from normal and cancer cells). Cybrids differing only in their mitochondrial composition will be examined for viability under metabolic stress, cell cycle distribution, production of reactive oxygen species, O$_2$ consumption, ATP synthesis, respiratory chain activity and capacity to grow in an anchorage independent manner. The effect of mitochondrial variants on nuclear gene expression will be studied using Western blotting and microarrays.

Body:
In the text to follow, we provide the Aims and original Statement of Work in italics with progress on the project presented in regular text.

**Aim 1: To examine the association between mitochondrial DNA variants and clinical outcome in African American men with prostate cancer.**

**Task 1: Extraction of all DNA for Initial Study and Validation Set**

*1a. Complete extraction of DNA/ quantitation of DNA for mitochondrial sequencing*  
(Extraction ongoing at present, expect more than 1,000 samples to be prepared before the project is funded. Additional 1,000 to be extracted for validation set IRB protocol already approved)

To date we have extracted DNA on more than 1500 Tissue samples from African American Men with Prostate cancer. Work was initially slower than we had initially planned because of difficulties with extracting adequate DNA from some of the FFPE (paraffin-embedded) samples. After significant technical difficulties we have now extracted adequate quantities of DNA from more than 1000 FFPE samples and 652 Frozen tissue samples and all of these samples have been sent for sequencing.
**Task 2: Mitochondrial Sequencing**

2a. Order and test overlapping mitochondrial primers with FFPE DNA to be sure that all primers work with FFPE tissue DNA
   Ongoing – Month 3

2b. Redesign/test and mitochondrial primers which do not give good PCR results in 2a.
   Months 4-6

2c. Establish Database for mitochondrial sequences
   Months 1-5

2d. PCR mitochondrial sequences for primary study and validation set
   Months 6-20

2e. Sequence mitochondrial PCR products
   Months 6-20

   (Illumina Admixture Genotyping to be supported by Helis funds, but performed simultaneously)

As reported in our initial project proposal, based on published sequences for mitochondrial PCR primers\(^1,2\) we designed 61 pairs of overlapping primers to amplify the entire 16.6-kb mitochondrial genome. In order to test this technology, we used 15 matched DNA samples derived from 5 patients – frozen tissue, FFPE tissue and whole genome amplified DNA samples derived from FFPE DNA for each patient. Overall 2/3 of the amplicons had reads in both directions on all 15 samples (including WGA DNA). Five of 61 amplicons failed completely and will be redesigned. Thus, we covered 93% of the genome by reads in at least one direction in 90% of the samples, and by reads in both directions in 84% of the mt genome, an excellent outcome for a first pass analysis over a target. Using these results, we identified 165 variants as compared to the published mitochondrial sequence. Within these variants there was 96-100% concordance of calls for each patient across the three sample types. We have continued to optimize the primers for the Sanger sequencing protocols, but as we reported in our initial application, we have also continued to test new technologies for mitochondrial sequencing. As we reported last year, we have obtained excellent results using a new technique developed by one of the collaborators on the this project (Dr. Lee-Jun Wong). This technique enriches the entire human mitochondrial genome by a single amplicon long-range PCR followed by massively parallel sequencing.\(^3\) This protocol utilizes less than 100 ng of tissue DNA and makes possible a one-step approach to provide quantitative base calls, exact deletion junction sequences and quantification of deletion heteroplasmy. As we reported last year, this strategy worked well for our frozen tissue DNA and we have now sequenced 652 samples using this technology.

We were not sure that this strategy will be effective in our FFPE DNA samples. Fortuitously we had a series of Frozen and FFPE samples derived from the same subject which we could use for comparison purposes. In the figures below we show the result from 4 such Frozen/FFPE pairs. To sequence FFPE samples, we used a sequence-specific capture approach followed by Illumina sequencing. We utilized a custom capture reagent (Roche NimbleGen) targeting the hg19 mitochondrial genome (16.6 Kb). Libraries of ~200 bp insert sizes were prepared from genomic DNA (500 ng) using HGSC Illumina WES protocol and co-captured at 24-48 plex using full-length blockers to capture reads at higher on-target rates. Libraries were pooled and sequenced on a single Illumina HiSeq 2500 lane (~30 Gb). We estimated that each sample would yield 312 Mb of sequence, which roughly would amount to 8000X depth across the target regions. This is a one third less average coverage to the 12000X coverage data currently generated for frozen tissue DNA samples using the long range PCR protocol, where 80 samples are sequenced per lane on Illumina HiSeq. As seen in the figures below, these estimates were relatively accurate with regard to coverage for the FFPE samples. We expected that duplicate rates, which are usually elevated in small target region captures, would not be an issue in this case, as mitochondrial DNA copy number is 1-2 log orders greater than that of the genomic DNA. Non-specific capture of Pseudogenes in the nuclear genome that share high sequence similarity with functional mtDNA genes is another valid concern when using the above described target enrichment approach. However, recent studies have shown that it is possible to bioinformatically determine the limit on heteroplasmy detection due to such contamination and largely eliminate this concern.\(^4\)
Figure 1A shows results from four samples sequenced by the long range primer technology. We now have sequenced 652 samples using this technology. As seen in figure 1A, a distinct advantage provided by amplification of the entire mitochondrial genome by long range PR with a single primer pair is the uniform coverage. This figure demonstrates that we routinely had coverage depth of 10,000-20,000-fold for the mitochondrial genome. This sequencing strategy has multiple advantages including ease of excluding nuclear DNA sequences which are nearly identical to mtDNA and more uniform coverage of the mitochondrial genome because there is much less risk of having a rare or novel variant at the primer binding site when only one set of primers is used. Deep coverage allows much more accurate base calls and improves the limit of detection for heteroplasmy from about 15% with Sanger sequencing to ~ 1-2% with the long range primer technique. Figure 1B shows sequence data from FFPE DNA samples derived from the same 4 patients; these sequences have been performed in duplicate (data not show) with similar results. Note that as we predicted, coverage depth for the FFPE DNA samples was more like 8000X across the target region. Some question has arisen as to why the depth of coverage is not uniform over the entire mitochondrial genome (sawtooth pattern). We feel this may relate to the GC content of the mitochondrial genome which demonstrates a very similar sawtooth pattern, but we do not feel it will affect our overall results.

**Figure 1: Mitochondrial DNA sequence data**

**Figure 1A:** Panels A-D show representative coverage for 4 different DNA samples across the entire 16,569 bp mitochondrial genome. The y axis represents fold coverage at each position (x coordinate) along the mitochondrial genome.
Using this data we were able to compare SNP counts in Frozen vs FFPE DNA samples. These data (figure 2) demonstrate that similar numbers of SNPs were called in Frozen and FFPE samples. Figure 3 shows that these SNPs were not completely concordant and we are working to resolve this issue at present.
Figure 2  Mitochondrial SNP counts in Frozen and FFPE DNA samples derived from the same patient

SNP counts

Figure 3  Mitochondrial SNP comparison in Frozen and FFPE DNA samples derived from the same patient

SNP comparison (FFPE vs Frozen DNA)
Task 3: Analysis of Mitochondrial Data

3a. Analyze mitochondrial sequences and integrate with clinical data  Months 20-28

3b. Admixture analysis based on Illumina data  Months 20-28

3c. Identify mitochondrial variants of interest for cybrid study and match with lymphoblast bank  Months 26-28

Figure 2A demonstrates the single nucleotide variant (SNV) calls for the first approximately two hundred subjects. On average each subject has about 150 SNVs with the Cambridge mitochondrial sequence used as reference.\textsuperscript{5,6} As shown in our previous report, most of the data at each coordinate clustered at 0 or 1. Since the mitochondrial genome is essentially haploid this suggests there is little contamination with nuclear DNA sequences. Similar data for insertions and deletions is shown in figure 2B.

**Figure 2:** Single nucleotide variants in the mitochondrial genome for the first sequenced subjects.

![Figure 2A: Single nucleotide variants in the mitochondrial genome for the first sequenced subjects.](image1)

![Figure 2B: Insertions and Deletions in the mitochondrial genome for the first sequenced subjects.](image2)
We have now created a database of the sequence data which will ultimately include not just mtDNA sequence data, but nuclear SNPs gleaned from the Illumina Race/Ethnicity panel (see below). We have mapped these sequences to the mitochondrial genome (see figure 3 below) to demonstrate the distributions of the mutations found in the various mitochondrial genes. Mutations below the 0.01 variant ratio have been filtered out. Figure 3A shows the SNVs in the mitochondrial genes. As expected the most mutations are seen in the D-loop, but a significant number of additional mutations are found in other regions of the genome as well including the coding regions of for a number of components of the electron transport chain. Similar data in Figure 3B shows the distribution of insertions and deletions across the mitochondrial genes.

**Figure 3:** Distribution of variants found in mitochondrial genes for the initial subjects.

![Figure 3A](image)

**Figure 3A:** Distribution of mitochondrial single nucleotide variants found within various mitochondrial genes for the initial subjects as compared to the Cambridge reference sequence. The Y axis represents the absolute number of variants observed within each gene.

![Figure 3B](image)

**Figure 3B** Unique insertions and deletions by gene across the initial patients as compared to the Cambridge reference sequence. The Y axis represents the absolute number of insertions/deletions observed within each gene.
Although not covered by this project, we have also sent the first 72 samples for genotyping on the Illumina African American Admixture panel. All 72 samples were successfully genotyped.

**Aim 2:** To understand the role of mitochondrial DNA variants in regulation of cellular processes important in the cancer cell including those involved with generation of reactive oxygen species and energy metabolism.

**Task 1: Creation of Cybrid cell lines**

1a. IRB submission for creation of lymphoblastoid lines from patients  
   Months 1-4

1b. Creation of immortalized lymphocyte bank for use in study  
   Months 5-24

1c. Order/test primers for variable number tandem repeat studies of nuclear origin  
   Months 6-12

1d. Deplete prostate cancer cells of mitochondria  
   3 potential cell lines to be used: PNT1A, LNCaP or PC3  
   Months 9-24

1e. Create cytoplasts and fuse with prostate cancer cells devoid of mitochondria to create cybrid cell lines  
   Months 20-36

1f. Confirm nuclear origin of cybrid cell lines using variable length tandem repeat in insulin receptor and other genes  
   Months 20-36

**Task 2: Testing of cybrid cells lines**

2a. Proliferation and cell cycle testing, Oxygen consumption, Production of reactive oxygen species, electron transport chain analysis, analysis of anchorage-independent cell growth  
   Months 22-40

In the last progress report, we reviewed the technical difficulties encountered during the generation of cybrid models using the ethidium bromide (EBr)-mediated mitochondrial DNA (mtDNA) depletion method. During the past year, we continued our original cybrid protocol using the EBr method by varying treatment conditions. Unfortunately, despite our best efforts, quantitative real time PCR (qPCR) analysis suggested a lack of complete mtDNA depletion in these cell lines (rho zero cells). Without the rho zero cells, we could not generate cybrids in prostate cancer models using the original protocol. To overcome these difficulties, we tested multiple alternative approaches including rhodamine-6G (R6G) mediated short-term mitochondrial dysfunction in generating rho zero cells. We used the benign prostate cell line PNT1A and the prostate cancer cell line PC3. Generation of rho zero using another prostate cancer cell line, LNCaP, was not successful due to low adherence of these cells to the bottom of cell culture plates after treatment with mtDNA depletion agents. Lack of adherence has made separation of viable rho zero cells very difficult.

Repeated efforts using R6G treatment finally succeeded in the generation of PNT1A rho zero; we have not yet been successful with the PC3 cells, which did not survive the rho zero condition. Cybrid models were then generated in the PNT1A benign prostate nuclear background. Mitochondria from enucleated metastatic prostate cancer cell line PC3 or benign prostate cell line PNT1A were fused with the rho zero PNT1A nuclear donor to form the cybrids (PC3/PNT1A and PNT1A/PNT1A respectively). We did extensive analysis of these cybrids to confirm their mitochondrial and nuclear identity. We sequenced multiple regions of mtDNA to confirm the mitochondrial identity (Figure 1). Similarly, we sequenced several nuclear SNP markers (Figure 2) as well as short tandem repeat (STR) markers (Figure 3) to confirm the nuclear identity of the cybrids. These analyses confirmed that both PC3/PNT1A and PNT1A/PNT1A cybrids contain PNT1A benign nuclear background but mitochondria from PC3 and PNT1A, respectively.

In order to confirm the role of mitochondrial retrograde regulation of cancer mitochondria in a nuclear background we analyzed the cancer property of these cybrids. We used the soft agar colony formation assay with similar number of PC3 and PNT1A parental cell lines as well as PC3/PNT1A and PNT1A/PNT1A cybrids under uniform experimental conditions. We observed that the while PNT1A/PNT1A cybrid which contain both nucleus and mitochondria from the benign cell line rarely form colonies in the soft agar like PNT1A parental
cells, PC3/PNT1A cybrid with cancer mitochondria could grow anchored dependently in the soft agar (Figure 4).

**Figure-1: Confirmation of mitochondria by sequencing mtDNA of parental cells and cybrids**

- **MTRNR2**
  - PNT1A-WT: T
  - PC3-WT: T>C
  - PNT1A/PNT1A: T
  - PC3/PNT1A: T>C

- **COX-1**
  - PNT1A-WT: C
  - PC3-WT: C>T
  - PNT1A/PNT1A: C
  - PC3/PNT1A: C>T

- **D-LOOP**
  - PNT1A-WT
  - PC3-WT: C>T
  - PNT1A/PNT1A
  - PC3/PNT1A: C>T
Figure-2: Confirmation of nucleus by sequencing random SNPs in nuclear DNA

**PNT1A-WT**

<table>
<thead>
<tr>
<th>No.</th>
<th>Sample File</th>
<th>Dir</th>
<th>Gene</th>
<th>Exon</th>
<th>Start</th>
<th>End</th>
<th>Size</th>
<th>Quality</th>
<th>Mut#</th>
<th>Mutation1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PNT1A-InGc-1F_2013-10-22_B01.ab1</td>
<td>1-F</td>
<td>InternalGC-01</td>
<td>chr1</td>
<td>-66</td>
<td>68</td>
<td>111</td>
<td>114</td>
<td>1</td>
<td>0.2C&gt;GA,p.S1WX</td>
</tr>
<tr>
<td>2</td>
<td>111</td>
<td>14</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>PNT1A-InGc-5F_2013-10-22_B03.ab1</td>
<td>3-F</td>
<td>InternalGC-06</td>
<td>chr11</td>
<td>-55</td>
<td>48</td>
<td>110</td>
<td>9</td>
<td>1</td>
<td>0.2C&gt;CT,p.R1TM</td>
</tr>
<tr>
<td>4</td>
<td>104</td>
<td>20</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>PNT1A-InGc-8F_2013-10-22_B06.ab1</td>
<td>5-F</td>
<td>InternalGC-09</td>
<td>chr15</td>
<td>-56</td>
<td>61</td>
<td>106</td>
<td>8</td>
<td>1</td>
<td>0.2T&gt;A,p.H1N</td>
</tr>
<tr>
<td>6</td>
<td>106</td>
<td>8</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>PNT1A-InGc-1F_2013-10-22_B07.ab1</td>
<td>7-F</td>
<td>InternalGC-12</td>
<td>chr20</td>
<td>-51</td>
<td>66</td>
<td>106</td>
<td>36</td>
<td>1</td>
<td>0.2T&gt;GA,p.L1RQ</td>
</tr>
<tr>
<td></td>
<td>106</td>
<td>36</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PC3-WT**

<table>
<thead>
<tr>
<th>No.</th>
<th>Sample File</th>
<th>Dir</th>
<th>Gene</th>
<th>Exon</th>
<th>Start</th>
<th>End</th>
<th>Size</th>
<th>Quality</th>
<th>Mut#</th>
<th>Mutation1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PC3-InGc-1F_2013-10-22_C01.ab1</td>
<td>1-F</td>
<td>InternalGC-01</td>
<td>chr1</td>
<td>-66</td>
<td>68</td>
<td>111</td>
<td>20</td>
<td>1</td>
<td>0.2C&gt;GA,p.S1WX</td>
</tr>
<tr>
<td>2</td>
<td>111</td>
<td>20</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>PC3-InGc-5F_2013-10-22_C02.ab1</td>
<td>5-F</td>
<td>InternalGC-06</td>
<td>chr11</td>
<td>-55</td>
<td>48</td>
<td>110</td>
<td>9</td>
<td>1</td>
<td>0.2C&gt;CT,p.R1TM</td>
</tr>
<tr>
<td>4</td>
<td>104</td>
<td>18</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>PC3-InGc-8F_2013-10-22_C06.ab1</td>
<td>8-F</td>
<td>InternalGC-12</td>
<td>chr20</td>
<td>-51</td>
<td>66</td>
<td>106</td>
<td>36</td>
<td>1</td>
<td>0.2T&gt;GA,p.L1RQ</td>
</tr>
<tr>
<td></td>
<td>106</td>
<td>36</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PNT1A/PNT1A**

<table>
<thead>
<tr>
<th>No.</th>
<th>Sample File</th>
<th>Dir</th>
<th>Gene</th>
<th>Exon</th>
<th>Start</th>
<th>End</th>
<th>Size</th>
<th>Quality</th>
<th>Mut#</th>
<th>Mutation1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PNT1A-InGc-1F_2013-10-22_B101.ab1</td>
<td>1-F</td>
<td>InternalGC-01</td>
<td>chr1</td>
<td>-66</td>
<td>68</td>
<td>111</td>
<td>114</td>
<td>1</td>
<td>0.2C&gt;GA,p.S1WX</td>
</tr>
<tr>
<td>2</td>
<td>111</td>
<td>14</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>PNT1A-InGc-5F_2013-10-22_B03.ab1</td>
<td>3-F</td>
<td>InternalGC-06</td>
<td>chr11</td>
<td>-55</td>
<td>48</td>
<td>110</td>
<td>9</td>
<td>1</td>
<td>0.2C&gt;CT,p.R1TM</td>
</tr>
<tr>
<td>4</td>
<td>104</td>
<td>20</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>PNT1A-InGc-8F_2013-10-22_B06.ab1</td>
<td>5-F</td>
<td>InternalGC-09</td>
<td>chr15</td>
<td>-56</td>
<td>61</td>
<td>106</td>
<td>8</td>
<td>1</td>
<td>0.2T&gt;A,p.H1N</td>
</tr>
<tr>
<td>6</td>
<td>106</td>
<td>8</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>PNT1A-InGc-1F_2013-10-22_B07.ab1</td>
<td>7-F</td>
<td>InternalGC-12</td>
<td>chr20</td>
<td>-51</td>
<td>66</td>
<td>106</td>
<td>36</td>
<td>1</td>
<td>0.2T&gt;GA,p.L1RQ</td>
</tr>
<tr>
<td></td>
<td>106</td>
<td>36</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PC3/PNT1A**

<table>
<thead>
<tr>
<th>No.</th>
<th>Sample File</th>
<th>Dir</th>
<th>Gene</th>
<th>Exon</th>
<th>Start</th>
<th>End</th>
<th>Size</th>
<th>Quality</th>
<th>Mut#</th>
<th>Mutation1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PC3_PNT1A-PLK01-InGc-1F_2013-10-22_E01.ab1</td>
<td>1-F</td>
<td>InternalGC-01</td>
<td>chr1</td>
<td>-66</td>
<td>68</td>
<td>111</td>
<td>28</td>
<td>1</td>
<td>0.2C&gt;GA,p.S1WX</td>
</tr>
<tr>
<td>2</td>
<td>111</td>
<td>28</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>PC3_PNT1A-PLK01-InGc-3F_2013-10-22_E02.ab1</td>
<td>3-F</td>
<td>InternalGC-06</td>
<td>chr11</td>
<td>-55</td>
<td>48</td>
<td>110</td>
<td>9</td>
<td>1</td>
<td>0.2C&gt;CT,p.R1TM</td>
</tr>
<tr>
<td>4</td>
<td>104</td>
<td>20</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>PC3_PNT1A-PLK01-InGc-8F_2013-10-22_E06.ab1</td>
<td>8-F</td>
<td>InternalGC-12</td>
<td>chr20</td>
<td>-51</td>
<td>66</td>
<td>106</td>
<td>36</td>
<td>1</td>
<td>0.2T&gt;GA,p.L1RQ</td>
</tr>
<tr>
<td></td>
<td>106</td>
<td>36</td>
<td>1</td>
<td>100.00%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 3  STR profiles of cybrids and parental cells

<table>
<thead>
<tr>
<th>Sample_Name</th>
<th>AMEL</th>
<th>CSF1PO</th>
<th>D13S317</th>
<th>D16S539</th>
<th>D18S51</th>
<th>D21S11</th>
<th>D3S1358</th>
<th>D5S818</th>
<th>D7S820</th>
<th>D8S1179</th>
<th>FGA</th>
<th>THO1</th>
<th>TPOX</th>
<th>vWA</th>
</tr>
</thead>
<tbody>
<tr>
<td>PNT1A-WT</td>
<td>X,Y</td>
<td>12</td>
<td>11,12</td>
<td>10,11</td>
<td>16</td>
<td>27,28</td>
<td>16</td>
<td>12</td>
<td>10,11</td>
<td>10,12</td>
<td>23,2</td>
<td>4,6</td>
<td>7,9</td>
<td>3,8</td>
</tr>
<tr>
<td>PC3/PNT1A-PLKO1</td>
<td>X,Y</td>
<td>12</td>
<td>11</td>
<td>10,11</td>
<td>16</td>
<td>27,28</td>
<td>16</td>
<td>12</td>
<td>10,11</td>
<td>10,12</td>
<td>24</td>
<td>6,7</td>
<td>9,3</td>
<td>8,11</td>
</tr>
<tr>
<td>PNT1A/PNT1A-PLKO1</td>
<td>X,Y</td>
<td>12</td>
<td>11,12</td>
<td>10,11</td>
<td>16</td>
<td>27</td>
<td>16</td>
<td>12</td>
<td>10,11</td>
<td>10,12</td>
<td>24</td>
<td>6,7</td>
<td>9,3</td>
<td>8,11</td>
</tr>
<tr>
<td>PC3-ATCC</td>
<td>X</td>
<td>11</td>
<td>11</td>
<td>11</td>
<td>13</td>
<td>8,11</td>
<td>6,7</td>
<td>8,9</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 4: Analysis of tumor properties in parentals and cybrids by colony formation assay

4A: Phase contrast images of soft agar colonies after two weeks of culture

4B: Number of colonies counted using Gelcount colony counter

- PNT1A-WT
- PC3-WT
- PNT1A/PNT1A
- PC3/PNT1A
Overall, during the past funding period we successfully generated cybrid models under benign prostate nuclear background and analyzed its genetic and tumor properties using different mitochondrial donors. We are continuing our efforts to generate new cybrid models with cancer nuclear background and to further characterize the already generated PNT1A cybrids.

Key Accomplishments:
1. Isolation of more than 90% of the DNA samples required for the entire project.
2. Validation of a more robust sequencing technique using single amplicon long-range PCR that permits deep coverage (10,000-20,000X on average) of the mitochondrial genome, to date 652 samples of Frozen Tissue DNA have been sequenced.
3. Validation underway for FFPE DNA samples using Sequence Capture
4. Mapping of the DNA variants to mitochondrial genes (data shown for ~first 200 samples). Additional data is available and we are mapping that data to the genes.
5. Cybrid models of benign (PNT1A) prostate cells have been successfully created and we are actively characterizing these cells. We are continuing to work with the PC3 cells with the expectation that we will be able to overcome the adhesion problem and create PC3 cybrids.

Reportable Outcomes:
No completed reportable outcomes have been accomplished as yet, but cybrid cell lines may soon be available. We are in the process of creating the Mitochondrial database with mtDNA sequence data, African American Admixture Data and Clinical Data.

Conclusions: Thus far we have made significant progress toward mitochondrial sequencing of the 2000 subject samples required for this project. In concert with Dr. David Wheeler in the Human Genome Sequencing Center and Dr. Lee-Jun Wong, we have implemented a new more rapid and much more powerful technique for sequencing mitochondrial DNA using single amplicon long-range PCR. This technology has permitted us to rapidly sequence 652 samples using NGS technology at a depth of coverage of 10,000-20,000X. This technology allows much more accurate base calls and improves the limit of detection for heteroplasmy from about 15% with Sanger sequencing to ~ 1-2% with the long range primer technique. This technology has permitted much more rapid generation of mtDNA sequence with much less DNA and less “contamination” by nuclear DNA. We are optimizing, sequencing strategies for the FFPE DNA and this is nearly complete. Once optimized, sequencing can be completed within a few weeks. Analysis of mitochondrial sequence with the 652 samples we now have in hand has begun in earnest and we will translate this data to the cybrid samples in the next few months. Finally though we have had to alter our strategy a bit, we have made significant progress in creating the cybrid cells required for our experiments. We have created viable PNT1A cybrids and we are presently characterizing these cells. Though PC3 cells have proven more difficult we continue to work with these cells and expect that we will shortly achieve PC3 rho zero cells. Nevertheless, we can work with the cybrids have have in hand to generate the data we need for our study.
References:


From: Shank, Patricia A CTR US ARMY MEDCOM USAMRMC (US)  
<patricia.a.shank7.ctr@mail.mil>
Sent: Tuesday, April 15, 2014 8:17 AM
To: Mims, Martha Pritchett
Cc: Bennett, Jodi H CIV US ARMY MEDCOM USAMRMC (US); Ittmann, Michael M; Katopol, Kristen R CTR US ARMY MEDCOM (US); Drayton, Maria A CTR US ARMY MEDCOM (US); Desir, Mirlene CIV US ARMY MEDCOM CDMRP (US); Miller, Theresa J CTR US ARMY MEDCOM CDMRP (US); Brosch, Laura R CIV US ARMY MEDCOM USAMRMC (US); King, Darlene; Evans, Sharon A CIV US ARMY MEDCOM USAMRMC (US);
Subject: A-17746.1, Continuing Review Acknowledgment Memorandum (Proposal Log Number PC101454/IRB Study Number H-30862, Award Number W81XWH-11-1-0737) (UNCLASSIFIED)

Classification: UNCLASSIFIED
Caveats: NONE


2. The USAMRMC ORP HRPO received the Baylor College of Medicine (BCM) Institutional Review Board (IRB) approval on 14 April 2014. The BCM IRB approved continuation of the subject protocol on 6 March 2014; this approval will expire on 5 March 2015.

3. This correspondence serves to acknowledge HRPO receipt of the continuing review documents for the protocol. No further action related to this continuing review is needed. The documents in support of this continuing review will be placed in the HRPO file.

4. Please note the following reporting requirements:

   a. Substantive modifications to the research protocol and any modifications that could potentially increase risk to subjects must be submitted to the HRPO for approval prior to implementation. The USAMRMC ORP HRPO defines a substantive modification as a change in Principal Investigator, change or addition of an institution, elimination or alteration of the consent process, change to the study population that has regulatory implications (e.g. adding children, adding active duty population, etc.), significant change in study design (i.e. would prompt additional scientific review), or a change that could potentially increase risks to subjects.
b. All unanticipated problems involving risk to subjects or others must be promptly reported by telephone (301-619-2165), by email (usarmy.detrick.medcom-usamrmc.other.hrpo@mail.mil), or by facsimile (301-619-7803) to the HRPO. A complete written report will follow the initial notification. In addition to the methods above, the complete report can be sent to the US Army Medical Research and Materiel Command, ATTN: MCMR-RP, 810 Schreider Street, Fort Detrick, Maryland 21702-5000.

c. Suspensions, clinical holds (voluntary or involuntary), or terminations of this research by the IRB, the institution, the sponsor, or regulatory agencies will be promptly reported to the USAMRMC ORP HRPO.

d. Events or protocol reports received by the HRPO that do not meet reporting requirements identified within this memorandum will be included in the HRPO study file but will not be acknowledged.

e. A copy of the continuing review approval notification by the BCM IRB must be submitted to the HRPO as soon as possible after receipt of approval. According to our records, it appears the next continuing review by the BCM IRB is due no later than 5 March 2016. Please note that the HRPO conducts random audits at the time of continuing review and additional information and documentation may be requested at that time.

f. The final study report submitted to the BCM IRB, including a copy of any acknowledgement documentation and any supporting documents, must be submitted to the HRPO as soon as all documents become available.

g. The knowledge of any pending compliance inspection/visit by the Food and Drug Administration (FDA), Office for Human Research Protections, or other government agency concerning this clinical investigation or research; the issuance of inspection reports, FDA Form 483, warning letters, or actions taken by any regulatory agencies including legal or medical actions; and any instances of serious or continuing noncompliance with the regulations or requirements must be reported immediately to the HRPO.

5. Please note: The USAMRMC ORP HRPO conducts site visits as part of its responsibility for compliance oversight. Accurate and complete study records must be maintained and made available to representatives of the USAMRMC as a part of their responsibility to protect human subjects in research. Research records must be stored in a confidential manner so as to protect the confidentiality of subject information.

6. Do not construe this correspondence as approval for any contract funding. Only the Contracting Officer/Grants Officer can authorize expenditure of funds. It is recommended that you contact the appropriate contract specialist or contracting officer regarding the expenditure of funds for your project.

7. The HRPO point of contact for this study is Patricia A. Shank, BSN, RN, CCRP, PMP, Human Subjects Protection Scientist, at 301-619-2282/email: patricia.a.shank7.ctr@mail.mil.

Regards,

Patricia A. Shank, BSN, RN, CCRP, PMP
Human Subjects Protections Scientist (General Dynamics IT)
Human Research Protection Office (HRPO)
Office of Research Protections (ORP)
U.S. Army Medical Research & Materiel Command (USAMRMC)
Fort Detrick, MD 21702-5102
Phone: 301-619-2282 or DSN 343-2282
Fax: 301-619-4165 or DSN 343-7803
Email: patricia.a.shank7.ctr@mail.mil

Mailing address:
Headquarters, U.S. Army Medical Research and Materiel Command
ATTN: MCMR-RPH/Patricia A. Shank, BSN, RN, CCRP, PMP
810 Schreider Street
Ft. Detrick, MD 21702-5000

Classification: UNCLASSIFIED
Caveats: NONE
From: Ittmann, Michael M
Sent: Friday, September 12, 2014 8:02 AM
To: Mims, Martha Pritchett
Subject: FW: A-17746.2 Continuing Review Acknowledgment Memorandum (Proposal Log Number PC101454, Award Number W81XWH-11-1-0737) (UNCLASSIFIED)

FYI

From: Sos, Alavy CTR USARMY MEDCOM USAMRMC (US) [mailto:alavy.sos2.ctr@mail.mil]
Sent: Thursday, September 11, 2014 4:00 PM
To: Ittmann, Michael M
Cc: Desir, Mirlene CIV USARMY MEDCOM USAMRAA (US); Brosch, Laura R CIV USARMY MEDCOM USAMRMC (US); Evans, Sharon A CIV USARMY MEDCOM USAMRMC (US); Bennett, Jodi H CIV USARMY MEDCOM USAMRMC (US); King, Darlene; Mims, Martha Pritchett; Sos, Alavy CTR USARMY MEDCOM USAMRMC (US); Miller, Theresa J CTR USARMY MEDCOM CDMRP (US); Kirdnual, Marsha L CTR USARMY MEDCOM (US); Englar, Nancy E CTR USARMY USAMC (US)
Subject: A-17746.2 Continuing Review Acknowledgment Memorandum (Proposal Log Number PC101454, Award Number W81XWH-11-1-0737) (UNCLASSIFIED)

Classification: UNCLASSIFIED
Caveats: NONE

SUBJECT: Acknowledgement of the Continuing Review documents for the protocol, "Molecular Correlates of Prostate Cancer Risk and Outcome," Submitted by Michael M. Ittmann, MD, PhD, Baylor College of Medicine, Houston, Texas, in Support of the Proposal, "Role of Mitochondrial Inheritance on Prostate Cancer Outcome in African American Men," Submitted by Martha P. Mims, MD, Baylor College of Medicine, Houston, Texas, IRB Study Number H-17002, Proposal Log Number PC101454, Award Number W81XWH-11-1-0737, HRPO Log Number A-17746.2


2. The USAMRMC ORP HRPO received the Baylor College of Medicine (BCM) Institutional Review Board (IRB) approval on 3 September 2014. The BCM IRB approved continuation of the subject protocol on 4 June 2014; this approval will expire on 3 June 2015.

3. This correspondence serves to acknowledge HRPO receipt of the continuing review documents for the protocol. No further action related to this continuing review is needed. The documents in support of this continuing review will be placed in the HRPO file.

4. Please note the following reporting requirements:

   a. Substantive modifications to the research protocol and any modifications that could potentially increase risk to subjects must be submitted to the HRPO for approval prior to implementation. The USAMRMC ORP HRPO defines a substantive modification as a change in Principal Investigator, change or addition of an institution, elimination or alteration of the consent process, change to the study population that has regulatory implications (e.g. adding children, adding active duty population,
etc.), significant change in study design (i.e. would prompt additional scientific review), or a change that could potentially increase risks to subjects.

b. All unanticipated problems involving risk to subjects or others must be promptly reported by telephone (301-619-2185), by email (usarmy.detrick.medcom-usamrmc.other.hrpo@mail.mil), or by facsimile (301-619-7803) to the HRPO. A complete written report will follow the initial notification. In addition to the methods above, the complete report can be sent to the US Army Medical Research and Materiel Command, ATTN: MCMR-RP, 810 Schreider Street, Fort Detrick, Maryland 21702-5000.

c. Suspensions, clinical holds (voluntary or involuntary), or terminations of this research by the IRB, the institution, the sponsor, or regulatory agencies will be promptly reported to the USAMRMC ORP HRPO.

d. Events or protocol reports received by the HRPO that do not meet reporting requirements identified within this memorandum will be included in the HRPO study file but will not be acknowledged.

e. A copy of the continuing review approval notification by the BCM IRB must be submitted to the HRPO as soon as possible after receipt of approval. According to our records, it appears the next continuing review by the BCM IRB is due no later than 3 June 2015. Please note that the HRPO conducts random audits at the time of continuing review and additional information and documentation may be requested at that time.

f. The final study report submitted to the BCM IRB, including a copy of any acknowledgement documentation and any supporting documents, must be submitted to the HRPO as soon as all documents become available.

g. The knowledge of any pending compliance inspection/visit by the Food and Drug Administration (FDA), Office for Human Research Protections, or other government agency concerning this clinical investigation or research; the issuance of inspection reports, FDA Form 483, warning letters, or actions taken by any regulatory agencies including legal or medical actions; and any instances of serious or continuing noncompliance with the regulations or requirements must be reported immediately to the HRPO.

5. Please note: The USAMRMC ORP HRPO conducts site visits as part of its responsibility for compliance oversight. Accurate and complete study records must be maintained and made available to representatives of the USAMRMC as a part of their responsibility to protect human subjects in research. Research records must be stored in a confidential manner so as to protect the confidentiality of subject information.

6. Do not construe this correspondence as approval for any contract funding. Only the Contracting Officer/Grants Officer can authorize expenditure of funds. It is recommended that you contact the appropriate contract specialist or contracting officer regarding the expenditure of funds for your project.

7. The HRPO point of contact for this study is the undersigned at alavy.sos2.ctr@mail.mil or 301-619-1118.

8. The HRPO point of contact for this action is Marsha Kirdnual, BSCR, Continuing Review Analyst, at 301-619-3191//marsha.l.kirdnual.ctr@mail.mil.
Regards,

Alavy Sos, MS, CIP  
General Dynamics Information Technology in support of  
Human Research Protection Office  
Office of Research Protections  
US Army Medical Research and Materiel Command  

Classification: UNCLASSIFIED  
Caveats: NONE